![]() ![]() | Kahvecioglu, Z. C., Vandecasteele, S., Bougard, M., Rasson, O., Martens, C., Appels, M., Laurent, S., Saussez, S., & Burtea, C. (29 January 2025). A novel peptide-based therapeutic strategy for anaplastic thyroid carcinoma: Dual targeting of EGFR and PIP3 [Paper presentation]. TELEVIE SEMINAR 2025, Liège, Belgium. |
![]() ![]() | Kahvecioglu, Z. C., Vandecasteele, S., Bougard, M., Rasson, O., Martens, C., Appels, M., Laurent, S., Saussez, S., & Burtea, C. (29 November 2024). A breakthrough peptide therapy targeting EGFR and PIP3 to combat anaplastic thyroid cancer [Paper presentation]. PhysPhar Autumn meeting, brussels, Belgium. |
![]() ![]() | Kahvecioglu, Z. C., Vandecasteele, S., Bougard, M., Peeters, S., Laurent, S., Saussez, S., & Burtea, C. (22 October 2024). Novel approach in the treatment of anaplastic thyroid cancer using EGFR-and PIP3-targeted synthetic peptides to inhibit the PI3K/AKT/mTOR signaling pathway [Paper presentation]. 9th Annual Peptide Therapeutics Symposium, La Jolla, United States - California. |
![]() ![]() | Kahvecioglu, Z. C., Samuel Vandecasteele, Marine Bougard, Sarah Peeters, Laurent, S., Saussez, S., & Burtea, C. (17 October 2024). Novel approaches in targeted drug delivery systems based on engineered peptides for the treatment of anaplastic thyroid cancer [Paper presentation]. Journée scientifique de la Société Royale de Chimie "Bioinspired Chemistry: from Molecules to Cells", Mons, Belgium. |
![]() ![]() | Kahvecioglu, Z. C., Vandecasteele, S., Bougard, M., Sarah Peeters, Daubry, A., Laurent, S., Saussez, S., & Burtea, C. (06 February 2024). Toward the development of a novel drug using engineered peptides designed for EGFR-mediated drug delivery of an apoptosis inducer in anaplastic thyroid carcinoma [Paper presentation]. Télévie Seminar. |
![]() ![]() | Andre, S., Verteneuil, S., Ris, L., Kahvecioglu, Z. C., Nonclercq, D., De winter, J., Vander elst, L., Laurent, S., Muller, R., & Burtea, C. (29 December 2023). Modulation of Cytosolic Phospholipase A2 as a Potential Therapeutic Strategy for Alzheimer’s Disease. Journal of Alzheimer's Disease Reports, 7 (1), 1395-1426. doi:10.3233/adr-230075 ![]() ![]() |
![]() ![]() | Kahvecioglu, Z. C., Vandecasteele, S., Bougard, M., Peeters, S., Daubry, A., Journe, F., Laurent, S., Saussez, S., & Burtea, C. (24 November 2023). Innovative drug delivery system using EGFR-targeted engineered peptides in anaplastic thyroid cancer treatment [Poster presentation]. PhD Day SFMBBM 2023, Liège, Belgium. ![]() |
![]() ![]() | Kahvecioglu, Z. C., Vandecasteele, S., Bougard, M., Rogien, C., Daubry, A., Journe, F., Laurent, S., Saussez, S., & Burtea, C. (27 October 2023). Novel therapeutic approaches for EGFR-mediated drug delivery using engineered peptides in anaplastic thyroid cancer [Poster presentation]. Annual BACR Meeting 2023 Friday October 27th, CIRCADIAN CYCLE, CHRONOBIOLOGY AND CANCER, brussels, Belgium. ![]() |
![]() ![]() | Kahvecioglu, Z. C., Samuel Vandecasteele, Marine Bougard, Charlotte Rogien, Journe, F., Laurent, S., Saussez, S., & Burtea, C. (02 July 2023). Development of a novel EGFR-targeted peptide for targeted delivery of drugs in anaplastic thyroid cancer [Poster presentation]. PBA 2023 33rd International Symposium on Pharmaceutical and Biomedical Analysis, ankara, Turkey. ![]() |
![]() ![]() | Kahvecioglu, Z. C., Toulehohoun, A., Feudjio Tagny, D., Rogien, C., Vandecasteele, S., Journe, F., Laurent, S., Saussez, S., & Burtea, C. (02 February 2023). A study of combined targeted therapy and delivery, inducing an inhibition of PI3K/AKT/mTOR pathway in anaplastic thyroid cancer cells [Paper presentation]. 2023 Télévie Seminar, bruxelles, Belgium. |
![]() ![]() | Kahvecioglu, Z. C., Toulehohoun, A., Feudjio Tagny, D., Rogien, C., Vandecasteele, S., Rogien, C., Journe, F., Laurent, S., Saussez, S., & Burtea, C. (11 September 2022). Novel therapeutic strategy targeting the EGFR and inhibiting PI3K/AKT/mTOR pathway in anaplastic thyroid carcinoma [Poster presentation]. 12th International Symposium on Drug Analysis & 32nd International Symposium on Pharmaceutical and Biomedical Analysis, Mons, Belgium. ![]() |
Kahvecioglu, Z. C., Toulehohoun, A., Feudjio Tagny, D., Journe, F., Laurent, S., Saussez, S., & Burtea, C. (08 April 2022). PI3K/AKT/mTOR pathway inhibition and targeted drug delivery combined in a novel therapeutic strategy addressed to anaplastic thyroid carcinoma [Poster presentation]. Séminaire Télévie. ![]() |
![]() ![]() | Kahvecioglu, Z. C.* , Bruynbroeck, M., Gheysen, L., Journé, F., Laurent, S., Saussez, S., & Burtea, C.*. (22 September 2021). Delivery of a drug molecule to thyroid cancer cells via EGFR targeting [Poster presentation]. 'Adaptation of the tumour and its ecosystem to radiotherapies' workshop ,September 22nd-25th, 2021, Manoir de Kerdréan, Le Bono, France. ![]() |
![]() ![]() | Kahvecioglu, Z. C., Gheysen, L., Journe, F., Laurent, S., Saussez, S., & Burtea, C. (21 May 2021). Toward the development of peptide inhibitors targeted to PI3K/AKT signalling pathway for the therapy of anaplastic thyroid carcinoma [Poster presentation]. 27th Porto Cancer meeting Stemness & Metastasis: Advances in Research and Clinical Translation, Porto, Portugal. |
![]() ![]() | Kahvecioglu, Z. C. (2020). Prise en charge du patient atteint d'un carcinome rénal à cellules claires métastatiques: le profil métabonomique prédit-il la réponse au traitement? [Master’s dissertation, Université de Mons]. ORBi UMONS-University of Mons. https://orbi.umons.ac.be/handle/20.500.12907/11808 |
![]() ![]() | Colet, J.-M., Pamart, L., Tagliatti, V., Delsinne, V., & Kahvecioglu, Z. C. (2019). Biologie Générale Humaine : Travaux pratiques. |
![]() ![]() | Benourad, F., Kahvecioglu, Z. C., Youcef-Benkada, M., & Colet, J.-M. (09 October 2018). Protective potential of the essential oil of Thymus vulgaris L. against Dicofol-induced poisoning in rats as established through clinical chemistry, histopathology and 1H-NMR-based metabonomics. South Asian Journal of Experimental Biology, 8 (2), 49-56. ![]() |
![]() ![]() | Maurois, P., Conotte, R., Kahvecioglu, Z. C., & Colet, J.-M. (23 May 2018). Etude par approche métabonomique et histopathologique d'une surconsommation en saccharose chez la souris [Poster presentation]. 11e journées scientifiques du Réseau Francophone de Métabonomique et fluxomique, Liège, Belgium. |
Benourad, F., Kahvecioglu, Z. C., Youcef-Benkada, M., & Colet, J.-M. (12 February 2014). Prospective evaluation of potential toxicity of repeated doses of Thymus vulgaris L. extracts in rats by means of clinical chemistry, histopathology and NMR-based metabonomic approach. Drug Testing and Analysis, 6 (10), 1069-75. doi:10.1002/dta.1606 ![]() |
Hambye, S., Helvenstein, M., Verdy, L., Kahvecioglu, Z. C., Conotte, R., Vanden Eynde, J.-J., Colet, J.-M., & Blankert, B. (10 February 2014). Ultra High Performance Liquid Chromatography method for the determination of Pentamidine and analog in rat biological fluids. Journal of Pharmaceutical and Biomedical Analysis, 95, 54-60. ![]() |
![]() ![]() | Colet, J.-M., Conotte, R., Kahvecioglu, Z. C., & Matuszak, N. (01 September 2009). Long term metabolic changes induced inidiosyncrasy-like liver toxicity [Poster presentation]. 46th Congress of the European Societies of Toxicology - Eurotox 2009, Dresde, Germany. |
![]() ![]() | Colet, J.-M., Laurent, S., Kahvecioglu, Z. C., Boutry, S., Vander Elst, L., & Müller, R. N. (01 September 2009). Vectorization of Iron Oxide Nanoparticles with a Neuron-penetrating RVG Peptide: An Attempt to Cross the Blood Brain Barrier [Paper presentation]. World Molecular Imaging Congress, Montreal, Canada. |
Kahvecioglu, Z. C. (2008). Evaluation des effets pharmacologiques et toxiques d'un extrait méthanolique de Sattaga bowal [Master’s dissertation, Université de Mons]. ORBi UMONS-University of Mons. https://orbi.umons.ac.be/handle/20.500.12907/29275 |